For the estimated 60 percent of severe asthma patients driven by eosinophilic inflammation, the arrival of biologic therapies over the past decade was supposed to change everything. And for many, it did. But a stubborn subset of patients cycle through one biologic after another — mepolizumab, benralizumab, dupilumab — without finding adequate control. Now, a newly approved drug called depemokimab (brand name Exdensur) offers a genuinely different option: an ultra-long-acting anti-IL-5 antibody that requires only two injections per year and demonstrated a 72 percent reduction in exacerbations requiring hospitalization or emergency department visits in pooled clinical trial data. The FDA approved it on December 16, 2025, and its U.S.
launch is expected in early 2026. This matters beyond the pulmonology clinic. Readers of this site know that chronic inflammatory conditions — including poorly controlled asthma — are increasingly linked to accelerated cognitive decline and heightened dementia risk. Systemic inflammation, repeated hypoxic episodes from severe exacerbations, long-term oral corticosteroid use, and disrupted sleep all feed into brain health deterioration. Getting severe eosinophilic asthma under genuine control is not just a respiratory goal; it is a neuroprotective one. This article covers what makes depemokimab different from existing biologics, the new CHEST guidelines published in January 2026 that formalize when and how to switch biologics after treatment failure, emerging pipeline therapies targeting patients who still don’t respond, and what all of this means for the millions of people managing both severe asthma and concerns about long-term brain health.
Table of Contents
- What Makes Depemokimab Work When Other Eosinophilic Asthma Biologics Have Failed?
- When Should Patients Switch Biologics, and What Does the New CHEST Guideline Say?
- The Brain Health Connection — Why Uncontrolled Eosinophilic Asthma Accelerates Cognitive Decline
- How Does Depemokimab Compare to Other Biologics on Cost and Convenience?
- What Happens When All Current Biologics Fail? Emerging Therapies for Refractory Cases
- Navigating Biologic Therapy While Managing Dementia Caregiving
- What the Next Two Years Look Like for Eosinophilic Asthma Treatment
- Conclusion
- Frequently Asked Questions
What Makes Depemokimab Work When Other Eosinophilic Asthma Biologics Have Failed?
Depemokimab is not the first drug to target interleukin-5, the cytokine most responsible for eosinophil production and survival. Mepolizumab, approved in 2015, and reslizumab, approved in 2016, both neutralize IL-5. Benralizumab, approved in 2017, goes after the IL-5 receptor itself. So why would another anti-IL-5 drug succeed where those sometimes fall short? The answer lies in binding affinity and duration. Depemokimab was engineered as an ultra-long-acting monoclonal antibody with enhanced binding to IL-5, meaning it holds onto its target more tightly and for far longer than its predecessors. This translates to sustained eosinophil suppression over a full six months from a single subcutaneous injection — a dosing schedule no other asthma biologic can match. Mepolizumab requires injections every four weeks; benralizumab every eight weeks after an initial loading phase. The clinical data backs up the engineering.
In the SWIFT-1 trial, depemokimab reduced annualized asthma exacerbations by 58 percent compared to placebo over 52 weeks. The SWIFT-2 trial showed a 48 percent reduction over the same period. Critically, when both trials were pooled, clinically significant exacerbations — those requiring hospitalization or emergency department visits, the kind that carry real risk of hypoxic brain injury — dropped by 72 percent. The safety profile was essentially equivalent to placebo, with patients experiencing similar rates and severity of side effects. For someone who has already tried and partially failed on mepolizumab or benralizumab, depemokimab’s enhanced binding may provide the additional IL-5 suppression their disease requires. Consider a practical scenario: a 58-year-old patient with severe eosinophilic asthma who has been on mepolizumab for a year with only modest improvement. She still averages two exacerbations annually, each requiring a burst of oral prednisone — a drug with well-documented links to hippocampal atrophy, mood disturbances, and impaired memory consolidation. Under the new treatment landscape, her physician now has a mechanistically refined option that doesn’t require starting over with an entirely different pathway.
When Should Patients Switch Biologics, and What Does the New CHEST Guideline Say?
In January 2026, the American College of Chest Physicians published a landmark guideline — its first comprehensive set of recommendations specifically addressing biologic switching in severe adult asthma. The guideline establishes seven key recommendations, and the most consequential is this: patients who fail to show a meaningful clinical response after four to six months on a biologic should be considered for switching. A “good response” is defined as at least a 50 percent decrease in exacerbations combined with at least a 50 percent reduction in maintenance oral corticosteroid dose. Anything less, and the conversation about changing therapy should begin. The switching pathways are specific. If a patient fails omalizumab (the anti-IgE biologic approved back in 2003), the guideline recommends moving to an anti-IL-5 or anti-IL-5 receptor alpha agent, dupilumab, or tezepelumab.
If a patient fails an anti-IL-5 or anti-IL-5 receptor alpha biologic — which would include mepolizumab, reslizumab, or benralizumab — the recommendation is to switch to dupilumab or tezepelumab, with dupilumab favored specifically in steroid-dependent patients. If dupilumab itself fails, the path leads back to anti-IL-5/5Rα or tezepelumab, guided by the patient’s eosinophil count and fractional exhaled nitric oxide levels. However, here is an important caveat: these guidelines were finalized before depemokimab’s approval had fully entered clinical practice. It is not yet clear exactly where depemokimab will be inserted into these switching algorithms — whether it will be grouped with existing anti-IL-5 agents or treated as a distinct escalation step due to its enhanced binding and different pharmacokinetic profile. Clinicians navigating biologic switches in early 2026 will need to use judgment about whether a patient who partially responded to mepolizumab might benefit from depemokimab’s stronger IL-5 neutralization before jumping to an entirely different mechanistic class. This is a conversation worth having with a pulmonologist or allergist who stays current with the evolving evidence.
The Brain Health Connection — Why Uncontrolled Eosinophilic Asthma Accelerates Cognitive Decline
The link between severe asthma and brain health is more direct than most people realize. Each severe exacerbation carries the potential for transient hypoxia — reduced oxygen delivery to the brain. Repeated hypoxic episodes damage neurons, particularly in the hippocampus, the brain region most critical for memory formation and most vulnerable in early Alzheimer’s disease. A 2023 study published in the Journal of Allergy and Clinical Immunology found that patients with severe asthma had measurably faster rates of cognitive decline over a five-year follow-up compared to those with mild or well-controlled disease. Then there is the corticosteroid problem. Oral prednisone, the rescue drug of choice during exacerbations, is one of the most neurotoxic medications routinely prescribed.
Even short bursts — five to seven days, the typical exacerbation course — elevate cortisol to levels that impair synaptic plasticity and, with repeated exposure, contribute to hippocampal volume loss visible on MRI. Patients who require maintenance oral corticosteroids because their biologic isn’t working well enough face compounding neurological risk with every month of continued use. The CHEST guideline’s emphasis on reducing OCS dose by 50 percent as a marker of biologic success is not arbitrary — it reflects the clinical reality that steroid dependence carries consequences far beyond the lungs. This is precisely why effective biologic therapy matters for readers concerned about dementia prevention. A treatment like depemokimab, which achieves a 72 percent reduction in the most severe exacerbations and potentially allows further steroid tapering, does not just improve breathing. It reduces the cumulative inflammatory and pharmacological insults that age the brain prematurely. For caregivers managing a loved one who has both severe asthma and early cognitive impairment, pushing for optimized biologic therapy is a legitimate neuroprotective strategy.
How Does Depemokimab Compare to Other Biologics on Cost and Convenience?
Cost is a genuine barrier in biologic therapy, and depemokimab enters the market with a strategic pricing advantage. At an estimated $25,596 per year, it undercuts the two most commonly prescribed competitors: dupilumab (Dupixent), which exceeds $38,000 per year, and benralizumab (Fasenra), which runs approximately $30,000 per year. GSK, the manufacturer, is clearly positioning depemokimab as the value option — a calculation reflected in their projection of $4 billion in peak annual revenue, a figure that assumes significant market share capture from existing biologics. The convenience factor may be even more compelling than the price difference. Every other asthma biologic requires injections every two to eight weeks, meaning six to twenty-six clinic visits or self-injection sessions per year. Depemokimab requires two. For older adults, for patients with mobility limitations, for people juggling asthma management with dementia caregiving responsibilities, the difference between twelve monthly injections and two biannual ones is not trivial — it is the difference between a treatment that dominates your calendar and one that nearly disappears into it.
The injections must be administered by a healthcare provider (not self-injected at home), so each visit is a clinic appointment, but two appointments per year is a dramatically lighter burden than the alternatives. The tradeoff, however, is flexibility. With a six-month dosing interval, depemokimab is essentially irreversible for half a year once administered. If a patient has an unexpected adverse reaction or needs to switch therapies, they cannot simply stop taking a pill or skip a monthly injection. The drug will remain active in their system for months. For patients who have historically tolerated anti-IL-5 therapies well, this is unlikely to be a concern. But for someone trying a new mechanistic class for the first time, the commitment embedded in each injection is worth discussing frankly with their physician.
What Happens When All Current Biologics Fail? Emerging Therapies for Refractory Cases
Even with depemokimab added to the arsenal, some patients will remain refractory. Their eosinophilic asthma resists every available biologic, or their disease involves overlapping inflammatory pathways that no single-target therapy can adequately address. This is where the next generation of pipeline therapies becomes relevant, and the most promising candidates are targeting interleukin-33, a cytokine that sits even further upstream in the inflammatory cascade than IL-5 or IL-4/IL-13. Astegolimab, an anti-IL-33/ST2 antibody, produced encouraging Phase 2b results in the ZENYATTA trial: a 43 percent reduction in exacerbations at the 490 mg dose. What makes astegolimab particularly noteworthy is its performance in the eosinophil-low subgroup — patients with fewer than 300 cells per microliter — where it achieved a 54 percent reduction in exacerbations. This is the population that existing biologics often miss entirely, since most current therapies are designed for high-eosinophil patients.
Itepekimab, another anti-IL-33 antibody given at 300 mg subcutaneously every two weeks, showed benefits for asthma control, quality of life, and lung function as monotherapy. However, a combination study pairing it with dupilumab unexpectedly failed to outperform monotherapy — a surprising result suggesting that these pathways may not be simply additive. Tozorakimab, yet another anti-IL-33 agent, is being studied in the Phase IIa FRONTIER-3 trial at 600 mg subcutaneously every four weeks for early-onset eosinophilic moderate-to-severe asthma. A critical limitation: none of these IL-33-targeting therapies are approved yet. They remain in Phase 2 trials, meaning years of additional study likely stand between current data and any regulatory decision. Patients and caregivers should be aware of these pipeline options without assuming they are imminent. The relevant action today is to optimize the use of currently available biologics — including, now, depemokimab — and discuss clinical trial eligibility with a specialist if standard options have been exhausted.
Navigating Biologic Therapy While Managing Dementia Caregiving
For families where one person has severe eosinophilic asthma and another has dementia — or where the same individual is contending with both conditions — the logistics of biologic therapy become a caregiving challenge in their own right. Monthly clinic visits for injections compete with neurologist appointments, cognitive therapy sessions, and the daily demands of dementia care. Treatment adherence suffers when the calendar is already full, and missed doses of a biologic can trigger rebound exacerbations that land someone in the emergency department.
This is one of the most practical arguments for depemokimab’s twice-yearly dosing. Reducing injection visits from twelve or more per year to two frees up bandwidth for the family members and caregivers who are often managing multiple chronic conditions across multiple people simultaneously. It is also worth noting that severe asthma exacerbations in a dementia caregiver can be catastrophic to the care recipient — when the caregiver is hospitalized, the person with dementia may face a sudden, disorienting change in environment and routine that can accelerate behavioral symptoms. Keeping the caregiver’s asthma controlled is, in a real sense, part of the dementia care plan.
What the Next Two Years Look Like for Eosinophilic Asthma Treatment
The treatment landscape for severe eosinophilic asthma is shifting faster now than at any point since omalizumab’s approval in 2003. Depemokimab’s entry in early 2026 introduces the first biologic with a six-month dosing interval, directly challenging the established market positions of mepolizumab and benralizumab. The January 2026 CHEST guidelines provide the first formal switching framework, giving clinicians evidence-based pathways rather than trial-and-error improvisation. And the IL-33-targeting pipeline — astegolimab, itepekimab, tozorakimab — promises to extend biologic therapy to eosinophil-low patients who have been underserved by everything currently available.
For patients and families navigating these changes, the most important step is a candid conversation with a pulmonologist or allergist who is actively following the evolving evidence. If a current biologic is not achieving the CHEST guideline benchmarks — 50 percent reduction in exacerbations, 50 percent reduction in oral corticosteroid dose — after four to six months, switching is not failure. It is the recommended standard of care. And with depemokimab now available, there is one more option to try before concluding that the disease is truly refractory.
Conclusion
The approval of depemokimab marks a meaningful advance for the subset of severe eosinophilic asthma patients who have not responded adequately to existing biologics. Its enhanced IL-5 binding, twice-yearly dosing convenience, lower annual cost compared to dupilumab and benralizumab, and strong safety profile make it a compelling option — particularly for older adults and caregivers whose treatment burden directly affects brain health outcomes. The new CHEST biologic switching guideline provides the clinical framework for knowing when to make a change, and emerging IL-33-targeting therapies offer hope for the truly refractory cases that even current options cannot reach.
For anyone reading this with an eye toward dementia prevention or caregiving, the takeaway is clear: uncontrolled severe asthma is not just a respiratory problem. It is an ongoing source of neuroinflammation, hypoxic injury, and corticosteroid-driven brain damage. Every severe exacerbation avoided is a small but real neuroprotective victory. Optimizing biologic therapy — using the new tools and guidelines now available — is one of the most concrete steps a patient or caregiver can take to protect both lung function and cognitive function simultaneously.
Frequently Asked Questions
How is depemokimab different from mepolizumab if they both target IL-5?
Both are anti-IL-5 monoclonal antibodies, but depemokimab was engineered with enhanced binding affinity, meaning it attaches to IL-5 more tightly and lasts far longer. This allows twice-yearly dosing compared to mepolizumab’s monthly injections. The stronger binding may also provide more complete IL-5 suppression in patients who had only a partial response to mepolizumab.
Can I switch directly from my current biologic to depemokimab?
The January 2026 CHEST guideline recommends evaluating biologic response after four to six months, looking for at least a 50 percent reduction in exacerbations and oral corticosteroid dose. If your current biologic is not meeting those benchmarks, switching is appropriate. However, the specific transition protocol from one biologic to depemokimab should be determined by your prescribing physician, as wash-out periods and timing vary.
Does depemokimab help with asthma symptoms that are not driven by eosinophils?
Depemokimab is approved specifically for severe asthma with an eosinophilic phenotype. It targets IL-5, which is primarily involved in eosinophil biology. Patients whose asthma is driven by other mechanisms — such as neutrophilic inflammation or allergic pathways — are unlikely to benefit. For non-eosinophilic severe asthma, tezepelumab (anti-TSLP) has the broadest mechanism and works upstream of eosinophilic inflammation specifically.
Is there evidence that better asthma control actually protects brain health?
Multiple lines of evidence support this connection. Severe exacerbations cause transient hypoxia that damages hippocampal neurons. Oral corticosteroids, used to treat exacerbations, are associated with hippocampal volume loss and impaired memory. Systemic inflammation from poorly controlled asthma contributes to neuroinflammation, a known driver of Alzheimer’s pathology. Reducing exacerbations and steroid use through effective biologic therapy addresses all three of these pathways.
What should I do if I have already failed multiple biologics?
Discuss clinical trial eligibility with your pulmonologist. Emerging IL-33-targeting therapies like astegolimab have shown efficacy even in eosinophil-low patients who do not respond well to current biologics. Additionally, if you have tried an anti-IL-5 agent but not depemokimab specifically, its enhanced binding profile means it is not simply a repeat of the same approach. The CHEST guideline also outlines specific switching pathways depending on which biologic you tried and your current biomarker levels.
